证券日报网讯 1月26日，美诺华发布公告称，公司2025年度实现归属于母公司所有者的净利润预计为 10，000.00万元到12，300.00万元，与上年同期相比增加3，319.34万元到5，619.34万元，同比增加 49.69%到84.11%。 （编辑 王雪儿） ...

美诺华（603538）(603538.SH)发布2025年年度业绩预增公告，预计2025年度实现归属于母公司所有者 的净利润预计为1亿元至1.23亿元，与上年同期相比增加3,319.34万元到5,619.34万元，同比增加49.69% 到84.11%。 ...

智通财经APP讯，美诺华(603538.SH)发布2025年年度业绩预增公告，预计2025年度实现归属于母公司 所有者的净利润预计为1亿元至1.23亿元，与上年同期相比增加3,319.34万元到5,619.34万元，同比增加 49.69%到84.11%。 ...

Core Viewpoint - The company Meinuohua expects a significant increase in net profit for the year 2025, with projections indicating a growth of 49.69% to 84.11% compared to the previous year [1] Financial Projections - The company anticipates that the net profit attributable to shareholders will be between 100 million yuan and 123 million yuan for 2025, reflecting a year-on-year increase [1] - The net profit after deducting non-recurring gains and losses is expected to range from 80 million yuan to 95 million yuan, representing a year-on-year growth of 62.43% to 92.88% [1] Revenue Drivers - The primary reason for the projected profit increase is attributed to the anticipated rise in operating revenue for the year 2025 [1]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-011 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 2025 年年度业绩预增公告 扣除非经常性损益事项后，归属于母公司所有者的净利润预计为 8,000.00 万元到 9,500.00 万元,同比增加 3,074.67 万元到 4,574.67 万元，同 比增加 62.43%到 92.88%。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本期业绩预告适用于实现盈利，且净利润与上年同期相比上升 50%以上 的情形。 宁波美诺华药业股份有限公司（以下简称"公司"）2025 年度实现归属 于母公司所有者的净利润预计为 10,000.00 万元到 12,300.00 万元,与上年同期 相比增加 3,319.34 万元到 5,619.34 万元，同比增 ...

Core Viewpoint - The company Minova announced an expected net profit for the fiscal year 2025, projecting between 100 million to 123 million yuan, representing an increase of 33.19 million to 56.19 million yuan, with a growth rate of 49.69% to 84.11% compared to the previous year [1] Financial Performance - The expected non-net profit is projected to be between 80 million to 95 million yuan, an increase of 30.75 million to 45.75 million yuan, with a growth rate of 62.43% to 92.88% year-on-year [1] - The net profit for the same period last year was 66.81 million yuan, while the non-net profit was 49.25 million yuan [1] Revenue Drivers - The primary reason for the performance increase is attributed to the growth in operating revenue [1]

Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. announced that its subsidiaries have received the "High-tech Enterprise Certificate," allowing them to benefit from preferential tax policies for three years [1] Group 1: Company Announcements - Ningbo Meinuo's subsidiary Xuancheng Meinuo Pharmaceutical Co., Ltd. and its wholly-owned subsidiary Ningbo High-tech Zone Meinuo Pharmaceutical Innovation Research Institute Co., Ltd. received the high-tech enterprise certification [1] - The certification for Xuancheng Meinuo, the Innovation Research Institute, and Meinuo Tiankang is a re-certification following the expiration of their previous certificates [1] Group 2: Tax Benefits - The three companies will enjoy a corporate income tax rate of 15% for three years (2025, 2026, 2027) after obtaining the high-tech enterprise certification [1] - This tax benefit is in accordance with the "High-tech Enterprise Certification Management Measures" and the "Corporate Income Tax Law of the People's Republic of China" [1]

宁波美诺华药业股份有限公司 2026 年第一次临时股东会会议资料 宁波美诺华药业股份有限公司 2026 年第一次临时股东会会议资料 中国·宁波 二○二六年二月二日 召开地点：浙江省宁波市高新区梅墟街道菁华路 777 号 1 号楼 1 | | | 宁波美诺华药业股份有限公司 2026 年第一次临时股东会会议资料 会 议 议 程 一、会议时间、地点 召开时间：2026 年 2 月 2 日，14：00 二、会议议程 1、会议主持人宣布会议开始，推选计票人、监票人各两名； 2、董事会秘书宣读会议须知； 3、会议主持人介绍会议议案： | 非累积投票议案 | | | --- | --- | | 序号 1 | 议案名称 关于向下修正"美诺转债"转股价格的议案 | 4、董事会秘书简要介绍议案要点； 5、与会股东或股东代理人提问及对议案进行表决； 6、计票人计票，监票人监票并由主持人公布现场表决结果； 7、休会，等待汇总网络投票结果； 8、宣读公司股东会决议； 9、律师宣读法律意见书； 10、与会董事及董事会秘书签署股东会决议及会议记录； 11、宣布股东会闭幕。 三、投票方式：现场投票和网络投票相结合 网络投票系统：上海证券交 ...

Group 1 - The chemical pharmaceutical sector increased by 0.91% on January 23, with Guangshantang leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1] - Guangshantang's stock price rose by 20.00% to 96.28, with a trading volume of 185,500 shares [1] Group 2 - The main funds in the chemical pharmaceutical sector experienced a net outflow of 487 million yuan, while retail investors saw a net inflow of 1.12 billion yuan [2] - The stock performance of several companies showed varied results, with some experiencing declines, such as Xingqi Eye Medicine down 4.86% [2] - The trading volume and turnover for various companies in the sector were significant, with notable figures such as 1.62 billion yuan for Xingqi Eye Medicine [2] Group 3 - Guangshantang had a net inflow of 396 million yuan from main funds, while retail investors had a net outflow of 136 million yuan [3] - Other companies like Hancheng Group and Shutaishen also showed significant net inflows and outflows, indicating varied investor sentiment [3] - The data reflects a mixed investment environment within the chemical pharmaceutical sector, with both institutional and retail investors actively participating [3]

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2026-010 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 关于子公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,宁波美诺华药业股份有限公司（以下简称"公司"）控股子公司宣城美 诺华药业有限公司（以下简称"宣城美诺华"）收到安徽省工业和信息化厅、安 徽省财政厅、国家税务总局安徽省税务局联合颁发的《高新技术企业证书》，证 书编号为 GR202534001271，发证时间为 2025 年 10 月 28 日，有效期为三年。 宣城美诺华、创新研究院、美诺华天康的本次高新技术企业的认定均在原证 书有效期满后的重新认定，根据《高新技术企业认定管理办法》、《中华人民共和 国企业所得税法》等相关规定，宣城美诺华、创新研究院、美诺华天康自获得高 新技术企业认证通过后三年内（即 2025 年、2026 年、2027 年）可享受国家关于 高新技术企业的相 ...